The Association Between Left Ventricular Hypertrophy and Biomarkers in Patients on Continuous Ambulatory Peritoneal Dialysis

Sang-Ho Park, MD, Se-Whan Lee, MD, Seung-Jin Lee, MD, Won-Yong Shin, MD, Dong-Kyu Jin, MD, Hyo-Wook Gil, MD, Jong-Oh Yang, MD, Eun-Young Lee, MD and Sae-Yong Hong, MD
Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Korea

ABSTRACT

Background and Objectives: Left ventricular hypertrophy (LVH) is a major cardiovascular complication and an important predictor of mortality in patients with end stage renal disease. Some studies have shown that the serum aldosterone levels are correlated with LVH in non-diabetic patients undergoing hemodialysis. The objective of this study was to elucidate the relationships between serum biomarkers, including aldosterone, and echocardiographic findings, such as LVH, in patients on peritoneal dialysis. Subjects and Methods: Thirty patients on continuous ambulatory peritoneal dialysis (CAPD) for >12 months at Soonchunhyang University Cheonan Hospital were included. Transthoracic echocardiography was performed and the left ventricular mass index (LVMI) was calculated using the Devereux formula. Serum biomarkers (N-terminal pro B-type natriuretic peptide (NT-proBNP), troponin T, C-reactive protein, renin, and aldosterone) were measured. Results: Sixteen of 30 patients had LVH on the basis of the LVMI. The mean serum aldosterone level was 62.53 ± 60.73 pg/mL (range, 5.03–250.68 pg/mL). LVH, on the basis of the LVMI, was not correlated with the serum aldosterone level. The serum aldosterone levels were not associated with echocardiographic findings, even with co-existing diabetes mellitus. The LVMI had a negative correlation with the hemoglobin (r = -0.405, p = 0.029) and hematocrit (r = -0.374, p = 0.042), and a positive correlation with NT-proBNP (r = 0.560, p = 0.002). The other biomarkers (renin, aldosterone, troponin T, and C-reactive protein) were not correlated with the LVMI. The LVMI was correlated with the left atrium volume index (r = -0.675, p = 0.001). Conclusion: NT-proBNP is a good marker to predict LVH in patients undergoing CAPD. The serum aldosterone level is not correlated with LVMI, even with co-existing diabetes mellitus. (Korean Circ J 2009; 39:488-493)

KEY WORDS: Aldosterone; Left ventricular hypertrophy; Peritoneal dialysis; Type-B natriuretic peptide.

Introduction

Left ventricular hypertrophy (LVH) is a major cardiovascular complication and an important predictor of mortality in patients with end stage renal disease (ESRD). Wang et al. reported that patients undergoing peritoneal dialysis had decreased residual kidney function and cardiac hypertrophy that combined to adversely increase the overall mortality and risk of cardiovascular death.

Although echocardiography provides an assessment of LVH and is an important tool used for the evaluation of patients on dialysis, measurement of serum biomarkers that reflect myocyte injury is relatively simple, non-invasive, and may allow better characterization of the nature of cardiac disease when present. Cardiac troponin T (TnT) and N-terminal pro B-type natriuretic peptide (NT-proBNP) have been evaluated as putative prognostic markers of cardiovascular disease in patients with ESRD. TnT and NT-proBNP have been reported to be correlated with LVH in patients on dialysis.
sensitivity C-reactive protein (hsCRP), the prototype marker of inflammation, is highly associated with cardiovascular disease in patients with ESRD, and has been reported to be associated with LVH in patients on continuous ambulatory peritoneal dialysis (CAPD).  

Serum aldosterone levels have been associated with various pathologic patterns of the left ventricle in patients with essential hypertension. In patients with primary hyperaldosteronism, the early onset of LVH and its reversal after treatment is well-known. The primary role of aldosterone in circulatory homeostasis and salt/water balance is thought to be mediated by the epithelial mineralcorticoid receptor. In addition, aldosterone binds to myocardial mineralocorticoid receptors and enhances extracellular matrix and collagen deposition in the heart. Aldosterone antagonists have been used in congestive heart failure patients with normal renal function. Some cases have been reported in which the use of spironolactone improves cardiac function without hyperkalemia in peritoneal dialysis patients. Recently, two studies have shown that the left ventricular mass index (LVMI) and serum aldosterone levels are correlated among non-diabetic patients undergoing hemodialysis, and the plasma aldosterone level is independent of blood pressure.

However, there have been few studies demonstrating a correlation between the LVMI and plasma aldosterone in CAPD patients. We hypothesized that aldosterone could be a useful serum biomarker in predicting LVMI. Because there is a need to determine the best biomarker for predicting LVH, we investigated the relationship between serum biomarkers (TnT, NT-proBNP, CRP, renin, and aldosterone) and LVH in patients on peritoneal dialysis.

**Subjects and Methods**

**Patients**

Thirty patients were eligible for the study. The inclusion criteria were continuous peritoneal dialysis treatment for ≥12 months, and no underlying malignancy, chronic liver disease, systemic lupus erythematosus, chronic rheumatic heart disease, or congenital heart disease. All patients had stable body weight and volume status. On physical examination, pretibial pitting edema was not observed and there was no pleural effusion on chest radiography. The heights and weights of all subjects were recorded. The body mass index (BMI) was calculated as the weight (kg)/height (m²).

The blood pressure and body weight were measured before instillation of the dialysate in the peritoneal equilibrium test (PET). The Investigational Review Board of the Cheonan Hospital at Soonchunhyang University approved this study. Informed consent was obtained from all patients who participated in the study.

**Biochemical determinations**

Blood samples were collected at baseline before PET with patients in the supine position. The plasma was separated after centrifugation at 2,000 g for 15 minutes; the supernatant was stored at -70°C until used. Routine blood chemistry was performed using standard techniques (76600-020; Hitachi, Japan). Commercially available radioimmunoassay kits were used to measure plasma concentrations of renin (Renin Riaead; Dainabot, Tokyo, Japan), aldosterone (Immunotech SA, France), and intact parathyroid hormone (PTH) (iPTH, PTH-120 MIN IRMA; BioSource Europe SA, Belgium). The hsCRP was measured by a latex high sensitivity assay. The TnT was measured by an electrochemiluminescence assay (Roche modular analyzer; Roche Diagnostic GmbH, Mannheim, Germany).

**Echocardiographic measurements**

Two-dimensional echocardiography was performed using a Vivid T-dimension (GE, VingMed, Horten, Norway) with a 3.5 MHz probe in subjects lying in the left decubitus position by a single experienced (10 year) echocardiographer blinded to all clinical details about the patients. All findings were confirmed by the cardiologist blinded to all of the patients’ clinical details.

Left ventricle (LV) mass was normalized for height²⁄³ and expressed as the LVMI. The LV mass was obtained by the LV short-axis dimension and a simple geometric formula. According to Devereux et al., the following equation provides a reasonable determination of LV mass in grams: 1.04 (LVID + PWT + IVST)²⁄³ - LVID³ x 0.8 + 0.6, where left ventricular internal diameter at end-diastole (LVID) represents the internal dimension at diastole, posterior wall thickness (PWT) represents the PWT, interventricular septal thickness (IVST) represents the interventricular septal thickness, 1.04 is the specific gravity of the myocardium, and 0.8 is the correction factor. The height-based indexing of the left ventricular mass (LVM) was specifically chosen to minimize the potential distortion by extracellular volume expansion (body surface area indexing is weight-sensitive).

An LVMI value >47 g/m² in women and >50 g/m² in men was considered an indication of LVH. The relative wall thickness (RWT) was calculated as PWT/2/LVDD, and a value >0.45 was considered to be increased. Using the criteria established by Korn et al., patients with an increased LVMI and increased RWT were considered to have eccentric LV hypertrophy, and those with a normal RWT were considered to have concentric LV hypertrophy.

Pulse Doppler echocardiography was used to assess LV diastolic function. The peak velocity of the early diastolic filling wave (E wave) and atrial filling (A wave) were recorded and the E-to-A ratio (E/A) was calculated. The ventricular filling pressure was estimated by
combining the mitral inflow early diastolic velocity (E) and the annulus velocity (E'). The patients were classified according to the E/E' ratio at rest. A value >15 was considered an indication of diastolic dysfunction.

To estimate the left atrium (LA) volume, the biplane area-length formula was used: 8/3 π ((A1) (A2)/L), where A1 and A2 represent the maximal planimetered LA area acquired from the apical 4- and 2-chamber views, respectively, and L is length. The LA volume index was calculated as the LA volume/body surface area.

### Statistical analysis

Data are presented as the mean ± SD. A probability value of a p<0.05 was considered statistically significant. All statistical analyses were performed using Statistical Package for Social Science (SPSS) for Windows (version 12.0; SPSS, Inc., Chicago, IL, USA). Continuous variables were analyzed using the Student’s t-test, and categorical variables were analyzed using the chi-square test. The Pearson correlation was used to identify the correlation between biomarkers and LVMI.

### Table 1. Demographic characteristics of the patients

| Age (years) | 51.9 ± 14.99 (29, 82) |
|------------|-----------------------|
| Gender (male : female) | 15 : 15 |
| Duration of peritoneal dialysis (months) | 37.77 ± 24.12 |
| Underlying diseases | |
| Diabetes | 18 |
| Hypertension | 4 |
| Chronic glomerulonephritis | 7 |
| Renal tuberculosis | 1 |
| Body mass index (kg/m²) | 25.2 ± 5.7 |
| Systolic blood pressure (mmHg) | 126.7 ± 13.8 |
| Diastolic blood pressure (mmHg) | 76.3 ± 11.0 |
| Albumin (mg/dL) | 3.71 ± 0.43 |
| Blood urea nitrogen (mg/dL) | 49.29 ± 17.84 |
| Creatinine (mg/dL) | 1.03 ± 0.82 |
| Hemoglobin (mg/dL) | 10.22 ± 0.95 |
| Hematocrit | 30.60 ± 1.46 |
| Renin activity (ng/mL/hr) | 8.81 ± 7.99 |
| Aldosterone (pg/mL) | 62.56 ± 60.73 |
| NT-ProBNP (pg/mL) | 5450.62 ± 8528.97 |
| TnT (ng/mL) | 0.04 ± 0.05 |
| hsCRP (mg/dL) | 0.57 ± 0.82 |

Table 2: Clinical and echocardiographic parameters

| All patients | Non-DM | DM |
|--------------|--------|----|
| Interventricular septal thickness (mm) | 10.08 ± 2.94 | 8.90 ± 2.86 | 10.86 ± 2.80 |
| Posterior wall thickness (mm) | 16.42 ± 9.98 | 18.84 ± 11.85 | 14.80 ± 8.48 |
| LV end diastolic diameter (mm)* | 48.72 ± 6.92 | 99.37 ± 36.44 | 68.85 ± 17.45 |
| LVMI (g/m²) | 51.87 ± 14.62 | 50.84 ± 18.71 | 52.56 ± 11.71 |
| Relative wall thickness | 0.44 ± 0.94 | 0.39 ± 0.88 | 0.48 ± 0.82 |
| LV ejection fraction (%) | 57.50 ± 8.42 | 57.12 ± 8.93 | 57.78 ± 8.31 |
| LA volume index (mL/m²) | 32.27 ± 12.58 | 36.16 ± 12.92 | 29.52 ± 11.96 |
| E/A ratio† | 0.95 ± 0.34 | 1.22 ± 0.30 | 0.73 ± 0.16 |
| E/E’ | 15.66 ± 5.27 | 13.56 ± 5.91 | 17.35 ± 4.16 |
| Renin activity (ng/mL/hr) | 11.87 ± 8.81 | 7.99 ± 6.30 | 14.45 ± 9.44 |
| Aldosterone (pg/mL) | 62.56 ± 60.73 | 78.99 ± 76.50 | 51.61 ± 46.77 |
| NT-ProBNP (pg/mL) | 5450.62 ± 8528.97 | 5105.74 ± 9918.56 | 5680.54 ± 7765.02 |
| TnT (ng/mL) | 0.04 ± 0.05 | 0.01 ± 0.01 | 0.06 ± 0.05 |
| hsCRP (mg/dL) | 0.57 ± 0.82 | 0.28 ± 0.42 | 0.76 ± 0.96 |

All values are the mean ± SD. †p<0.02 between non-DM and DM. ‡p<0.01 between non-DM and DM. DM: diabetes mellitus, LVMI: left ventricular mass index, LV: left ventricle, LA: left atrium, E/A ratio: ratio of early-to-late transmitral flow velocity, E/E: ratio of mitral inflow early diastolic velocity-to-annulus velocity, NT-ProBNP: N-terminal pro B-type natriuretic peptide, TnT: troponin T, hsCRP: high sensitivity C-reactive protein

### Results

#### Patients

The general characteristics of 30 patients on peritoneal dialysis are summarized in Table 1. Eighteen patients were diabetic, while 12 patients were non-diabetic. Two of the diabetic patients received oral hypoglycemia agents; the other patients received insulin injections. No patients were treated with thiazolidinedione. Antihypertensive drugs were used in 30 patients (angiotensin receptor blockers, n=28; calcium channel blockers, n=22; beta-blockers, n=14; minoxidil, n=2). The residual urine volume in 10 patients was <100 mL.

#### Correlation of aldosterone and the left ventricular mass index

The echocardiography findings are summarized in Table 2. Using the LVMI, 16 of 30 patients had LVH. The serum aldosterone and renin levels were not correlated with the LVMI regardless of the presence of di-
LVMI (g/m².7) 40.32 ± 0.88
hsCRP (mg/dL) 0.50 ± 0.47
TnT (ng/mL) 0.038 ± 0.07
Aldosterone (pg/mL) 70.54 ± 0.58
Renin activity (ng/mL/hr) 12.28 ± 0.44
Hematocrit 32.31 ± 0.12
Diastolic blood pressure (mmHg) 75.8 ± 9.05
Systolic blood pressure (mmHg) 124.7 ± 18.48
Age (years) 49.50 ± 13.02
Duration of peritoneal dialysis (months) 39.07 ± 23.32

Table 3. Comparison of variables with respect to left ventricular hypertrophy

| Patients without LVH | Patients with LVH | p     |
|----------------------|-------------------|-------|
| Duration of peritoneal dialysis (months) | 39.07 ± 21.97 | 36.63 ± 26.52 | 0.787 |
| Age (years) | 49.50 ± 15.4 | 54.00 ± 14.79 | 0.422 |
| Systolic blood pressure (mmHg) | 124.7 ± 14.4 | 128.4 ± 13.5 | 0.479 |
| Diastolic blood pressure (mmHg) | 75.8 ± 9.5 | 76.8 ± 12.5 | 0.815 |
| Hemoglobin (mg/dL) | 10.70 ± 0.97 | 9.84 ± 0.93 | 0.023 |
| NT-ProBNP (pg/mL) | 70.54 ± 12.51 | 55.58 ± 44.39 | 0.511 |
| TnT (ng/mL) | 0.038 ± 0.039 | 0.042 ± 0.580 | 0.829 |
| hsCRP (mg/dL) | 0.50 ± 0.88 | 0.63 ± 0.78 | 0.672 |
| LVMI (g/m².7) | 40.32 ± 5.16 | 61.98 ± 12.51 | <0.001 |
| RWT | 0.45 ± 0.12 | 0.44 ± 0.07 | 0.840 |
| LVEF (%) | 61.94 ± 4.83 | 53.36 ± 9.05 | 0.004 |
| E/E' | 13.05 ± 3.36 | 18.48 ± 5.60 | 0.005 |
| E/A | 0.98 ± 0.37 | 13.05 ± 3.36 | 0.623 |
| LA volume index (mL/m²) | 24.81 ± 6.55 | 39.23 ± 13.02 | 0.001 |

LVMI: left ventricular mass index, LA: left atrium, E/E': ratio of mitral inflow early diastolic velocity-to-annulus velocity, NT-ProBNP: N-terminal pro B-type natriuretic peptide. ProBNP: High sensitivity C-reactive protein, LVEF: left ventricular ejection fraction, E/A: ratio of the peak velocity of the early diastolic filling wave of atrial filling wave to the peak velocity of the early diastolic filling wave of mitral inflow. TnT: troponin T, hsCRP: High sensitivity C-reactive protein, LVEF: left ventricular ejection fraction, E/A: ratio of the peak velocity of the early diastolic filling wave of atrial filling wave to the peak velocity of the early diastolic filling wave of mitral inflow. TnT: troponin T, hsCRP: High sensitivity C-reactive protein, LVEF: left ventricular ejection fraction, E/A: ratio of the peak velocity of the early diastolic filling wave of atrial filling wave to the peak velocity of the early diastolic filling wave of mitral inflow.

Fig. 1. Relationship of LVMI and aldosterone or NT-proBNP. A: there was no relationship between LVMI and aldosterone. B: there was relationship between LVMI and NT-proBNP (r=0.560, p=0.002). LVMI: left ventricular mass index, DM: diabetes mellitus, NT-ProBNP: N-terminal pro B-type natriuretic peptide.

Comparison of diastolic markers with the other variables

According to the LA volume index, 16 patients had diastolic dysfunction (≥28 mL/m²). There were no significant differences in serum biomarkers between patients with diastolic dysfunction and those without diastolic dysfunction. The LVMI was significantly higher in patients with diastolic dysfunction (LA volume index...
In the current study, aldosterone was negatively correlated with systolic blood pressure, which is inconsistent with previous reports. There are no differences in the mean value of plasma aldosterone between normal subjects and hypertensive patients. Aldosterone antagonists have been shown to be effective in patients with heart failure and an acute myocardial infarction (MD) with adequate renal function. The use of aldosterone antagonists is generally contraindicated in severe renal dysfunction, although some cases have reported that spironolactone could improve cardiac function in ESRD patients. Once patients have progressed to ESRD, aldosterone levels may remain elevated. In theory, the elevation of aldosterone might injure cardiac muscle in ESRD patients. In a few studies involving hemodialysis patients, aldosterone was only correlated with the LVMI in non-dialysis patients. Our study showed that aldosterone was not correlated with the LVMI, even with co-existing DM. We reasoned that this difference could be influenced by dialysis modality and blood pressure. In Sato’s study, a decrease in aldosterone concentration before and after hemodialysis was significantly lower in patients with uncontrolled blood pressure than in patients with well-controlled blood pressure. In the current study, aldosterone was negatively correlated with systolic blood pressure, which is inconsistent with Sato’s study. Thus, aldosterone levels in CAPD patients might be more influenced by blood pressure than LVMI. In a study of 115 hypertensive patients, Malmqvist et al. reported plasma renin activity (PRA) and aldosterone, two markers of the angiotensin-aldosterone system (RAAS), were related to LV mass and RWT, whereas in a study of Korean 275 essential hypertensive patients, PRA was not related to LVMI. In our study, PRA was not related to LVMI. RAAS could be influenced by antihypertensive drugs, but in our study, the PRA and aldosterone level were not different according to use of antihypertensive drugs. The results of our study showed that NT-proBNP, among the biomarkers investigated, was correlated with the LVMI. This finding is consistent with previous reports. In our study, troponin T was not correlated with the LVMI and NT-proBNP. NT-proBNP is a superior marker for the prediction of the LVMI compared to TnT in patients receiving peritoneal dialysis. Concentric LVH has been shown to be associated with more marked vascular alterations in ESRD and a poorer patient outcome. Our results showed that NT-proBNP and residual renal function might be associated with LV geometry. These results suggest that a worsening of residual renal function might effect the concentric left ventricular remodeling and that NT-proBNP might be a good marker for concentric left ventricular remodeling.

In conclusion, the results of this study suggest that NT-proBNP is a good marker to predict LVH in CAPD patients and aldosterone was not correlated with LVMI, even with co-existing DM in stable CAPD patients.

REFERENCES

1) Foley RN, Parfrey PS, Hammet JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995;47:186-92.
2) Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989;36:286-90.
3) Wang Y, Wang M, Woo J, et al. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol 2004;15:2186-94.
4) Diris JH, Hackeng CM, Kooman JP, Pinto YM, Hermens WT, van Dieijen-Visser MP. Impaired renal clearance explains ele-

≥ 28 mL/m²) than in those without diastolic dysfunction (LA volume index < 28 mL/m²; 42.48 ± 8.63 vs. 59.12 ± 14.79 g/m²², p=0.001). The LA volume index was correlated with the LVMI (r=0.675, p<0.001). According to the E/E’, the renin activity was higher in patients with diastolic dysfunction (E/E’ ≥ 15) compared to the other patients (10.76 ± 2.88 vs. 4.67 ± 1.30, p = 0.04); however, NT-proBNP was not different between the two groups. The LVMI was significantly higher in patients with diastolic dysfunction (E/E’ ≥ 15) than in those without diastolic dysfunction (E/E’ < 15; 44.28 ± 10.11 vs. 50.03 ± 16.66 g/m²², p=0.025). The E/E’ was correlated with the LVMI (r=0.640, p<0.001). The E/A ratio was not correlated with the LVMI.

Discussion

Serum aldosterone has recently been reported to play a significant role in cardiac hypertrophy independent of its effect on blood pressure. There are no differences in the mean value of plasma aldosterone between normal subjects and hypertensive patients. Aldosterone antagonists have been shown to be effective in patients with heart failure and after an acute myocardial infarction (MD) with adequate renal function. The use of aldosterone antagonists is generally contraindicated in severe renal dysfunction, although some cases have reported that spironolactone could improve cardiac function in ESRD patients. Once patients have progressed to ESRD, aldosterone levels may remain elevated. In theory, the elevation of aldosterone might injure cardiac muscle in ESRD patients. In a few studies involving hemodialysis patients, aldosterone was only correlated with the LVMI in non-dialysis patients. Our study showed that aldosterone was not correlated with the LVMI, even with co-existing DM. We reasoned that this difference could be influenced by dialysis modality and blood pressure. In Sato’s study, a decrease in aldosterone was observed after hemodialysis, possibly due to volume status or clearance by dialysis; however, the volume status is steady in stable peritoneal dialysis. The control of blood pressure might influence the aldosterone level in ESRD. We previously reported that aldosterone concentrations before and after hemodialysis were significantly lower in patients with uncontrolled blood pressure than in patients with well-controlled blood pressure. In the current study, aldosterone was negatively correlated with systolic blood pressure, which is inconsistent with Sato’s study. Thus, aldosterone levels in CAPD patients might be more influenced by blood pressure than LVMI. In a study of 115 hypertensive patients, Malmqvist et al. reported plasma renin activity (PRA) and aldosterone, two markers of the angiotensin-aldosterone system (RAAS), were related to LV mass and RWT, whereas in a study of Korean 275 essential hypertensive patients, PRA was not related to LVMI. In our study, PRA was not related to LVMI. RAAS could be influenced by antihypertensive drugs, but in our study, the PRA and aldosterone level were not different according to use of antihypertensive drugs. The results of our study showed that NT-proBNP, among the biomarkers investigated, was correlated with the LVMI. This finding is consistent with previous reports. In our study, troponin T was not correlated with the LVMI and NT-proBNP. NT-proBNP is a superior marker for the prediction of the LVMI compared to TnT in patients receiving peritoneal dialysis. Concentric LVH has been shown to be associated with more marked vascular alterations in ESRD and a poorer patient outcome. Our results showed that NT-proBNP and residual renal function might be associated with LV geometry. These results suggest that a worsening of residual renal function might effect the concentric left ventricular remodeling and that NT-proBNP might be a good marker for concentric left ventricular remodeling.

In conclusion, the results of this study suggest that NT-proBNP is a good marker to predict LVH in CAPD patients and aldosterone was not correlated with LVMI, even with co-existing DM in stable CAPD patients.
vated troponin T fragments in hemodialysis patients. Circulation 2004;109:23-5.
5) Deegan PB, Lafferty ME, Blumsohn A, Henderson IS, McGregor E. Prognostic value of troponin T in hemodialysis patients is independent of comorbidity. Kidney Int 2001;60:2399-405.
6) deFilippi C, Wasserman S, Rosano S, et al. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA 2003;290:353-9.
7) Mallamaci F, Zoccali C, Parlongo S, et al. Diagnostic value of troponin T for alterations in left ventricular mass and function in dialysis patients. Kidney Int 2002;62:1884-90.
8) Wang AY, Lam CW, Yu CM, et al. N-terminal pro-brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients. J Am Soc Nephrol 2007;18:321-30.
9) Rossi GP, Sacchetto A, Visentin P, et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996;27:1039-43.
10) Denolle T, Chatellier G, Julien J, Battaglia C, Luo P, Plouin PF. Left ventricular mass and geometry before and after etiologic treatment in renovascular hypertension, aldosterone-producing adenoma, and pheochromocytoma. Am J Hypertens 1993;6:907-13.
11) Steigerwalt S, Zafar A, Mesha N, Gardin J, Provenzano R. Role of aldosterone in left ventricular hypertrophy among African-American patients with end-stage renal disease on hemodialysis. Am J Nephrol 2007;27:159-63.
12) Sato A, Funder JW, Saruta T. Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis. J Hypertens 1999;12:867-73.
13) Devereux RB, de Simone G, Koren MJ, Roman MJ, Laragh JH. Left ventricular mass as a predictor of development of hypertension. Am J Hypertens 1991;4:603S-7S.
14) Savage DD, Garrison RJ, Kannel WB, et al. The spectrum of left ventricular hypertrophy in a general population sample: the Framingham study. Circulation 1987;75:126-33.
15) Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345-52.
16) Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006;7:79-108.
17) Delles C, Schmidt BM, Muller HJ, Oehner S, Klingbeil AU, Schmieder RE. Functional relevance of aldosterone for the determination of left ventricular mass. Am J Cardiol 2003;91:297-301.
18) Song JS. Studies on plasma rennin and aldosterone in essential hypertension. Korean Circ J 1974;4:1-24.
19) Ratge D, Augustin R, Wisser H. Catecholamines, renin, aldosterone and arterial pressure in patients on chronic hemodialysis treatment. Int J Artif Organs 1983;6:255-60.
20) Hong ZR, Gil HW, Yang JO, Lee EY, Ahn JO, Hong SY. Associations between sympathetic activity, plasma concentrations of renin, aldosterone, and parathyroid hormone, and the degree of intractability of blood pressure control in hemodialysis patients. J Korean Med Sci 2007;22:604-10.
21) Malmqvist K, Ohman K, Lind L, Nystrom F, Kahan T. Relationships between left ventricular mass and the renin-angiotensin system, catecholamines, insulin and leptin. J Intern Med 2002;252:430-9.
22) Suh SY, Park CG, Chwe UR, et al. Plasma renin activity and clinical implication in Korean hypertensive patients. Korean Circ J 2005;35:658-64.
23) Roman MJ, Pickering TG, Schwartz JE, Pini R, Devereux RB. Relation of arterial structure and function to left ventricular geometric patterns in hypertensive adults. J Am Coll Cardiol 1996;28:751-6.
24) London GM, Guerin AP, Marchais SJ, et al. Cardiac and arterial interactions in end-stage renal disease. Kidney Int 1996;50:600-8.
25) Verdecchia P, Schillaci G, Borgioni C, et al. Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass. J Am Coll Cardiol 1995;25:871-8.
26) Choong CY, Herrmann HC, Weyman AE, Fifer MA. Preload dependence of doppler-derived indexes of left ventricular diastolic function in humans. J Am Coll Cardiol 1987;10:800-8.
27) Tsang TS, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. Am J Cardiol 2002;90:1284-9.
28) Cho HJ, Pyun WB, Shin GJ. The influence of the left ventricular geometry on the left atrial size and left ventricular filling pressure in hypertensive patients, as assessed by echocardiography. Korean Circ J 2009;39:145-50.